All In Biotech

Drug Trial Radar · NCT06757504

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 13, 2025

Primary completion

Feb 6, 2026

Study completion May 8, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.

Conditions

  • Autism Spectrum Disorder (ASD)

Interventions

  • TTYP01 Tablets (12mg or 18mg)Drug

    Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

  • Placebo (Simulant TTYP01 Tablets)Drug

    Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal) scores at Week 12.Time frame: At baseline and week 12
  2. Incidence and severity of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and TEAEs that lead to treatment discontinuation.Time frame: Throughout the trial period
  3. Plasma concentrations and population PK profiles of edaravone and its metabolites in adolescent and pediatric ASD participants.Time frame: Visit 2 (Day 1): 30 minutes (±5 minutes) and 3 hours (±10 minutes) after the first dose; Visit 8 (Week 12 ±2 Days)or Early withdrawal: before the first dose (0 hour), and 30 minutes (±5 minutes) after the first dose on the day of the visit.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Sixth Hospital

    Beijing, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Not yet recruiting

  • Nanjing Brain Hospital, The Affiliated Brain Hospital of Nanjing Medical University

    Nanjing, China · Not yet recruiting

  • Tianjin Mental Health Center

    Tianjin, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.